HTG Molecular Diagnostics Statistics
HTG Molecular Diagnostics (HTGMQ) Stock Statistics & Valuation Metrics
Total Valuation
HTG Molecular Diagnostics has a market cap or net worth of $2.00. The enterprise value is $7.21M.
- Market Cap
- $2.00
- Enterprise Value
- $7.21M
Share Statistics
HTG Molecular Diagnostics has 2,214,233 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,214,233
- Owned by Insiders
- ―
- Owned by Institutions
- 0.11%
Financial Efficiency
HTG Molecular Diagnostics’s return on equity (ROE) is -4.01 and return on invested capital (ROIC) is -151.00%.
- Return on Equity (ROE)
- -4.01
- Return on Assets (ROA)
- -1.21
- Return on Invested Capital (ROIC)
- -151.00%
- Return on Capital Employed (ROCE)
- -2.19
- Revenue Per Employee
- 120.12K
- Profits Per Employee
- -407.44K
- Employee Count
- 53
- Asset Turnover
- 0.36
- Inventory Turnover
- 5.03
Valuation Ratios
The current PE Ratio of HTG Molecular Diagnostics is -0.00. HTG Molecular Diagnostics’s PEG ratio is -0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- 0.00
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, HTG Molecular Diagnostics had revenue of 6.37M and earned -21.59M in profits. Earnings per share was -24.28.
- Revenue
- 6.37M
- Gross Profit
- 1.79M
- Operating Income
- -20.83M
- Pretax Income
- -21.58M
- Net Income
- -21.59M
- EBITDA
- -20.14M
- Earnings Per Share (EPS)
- -24.28
Cash Flow
In the last 12 months, operating cash flow was -16.83M and capital expenditures -20,867, giving a free cash flow of -16.85M billion.
- Operating Cash Flow
- -16.83M
- Free Cash Flow
- -16.85M
- Free Cash Flow per Share
- -20.73
Dividends & Yields
HTG Molecular Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8339744.34%
- Earnings Yield
- -24282991.71%
Stock Price Statistics
- Beta
- -269.52
- 52-Week Price Change
- -96.36%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
HTG Molecular Diagnostics upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- May 08, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
HTG Molecular Diagnostics as a current ratio of 1.89, with Debt / Equity ratio of 154.92%
- Current Ratio
- 1.89
- Quick Ratio
- 1.78
- Debt to Market Cap
- 30.99
- Net Debt to EBITDA
- 0.19
- Interest Coverage Ratio
- -24.31
Taxes
In the past 12 months, HTG Molecular Diagnostics has paid 10.84K in taxes.
- Income Tax
- 10.84K
- Effective Tax Rate
- -0.00
Enterprise Valuation
HTG Molecular Diagnostics EV to EBITDA ratio is 0.19, with an EV/FCF ratio of 0.21.
- EV to Sales
- -0.61
- EV to EBITDA
- 0.19
- EV to Free Cash Flow
- 0.21
- EV to Operating Cash Flow
- 0.21
Balance Sheet
HTG Molecular Diagnostics has $6.56M in cash and marketable securities with $3.98M in debt, giving a net cash position of $2.58M billion.
- Cash & Marketable Securities
- $6.56M
- Total Debt
- $3.98M
- Net Cash
- $2.58M
- Net Cash Per Share
- $1.17
- Tangible Book Value Per Share
- $0.21
Margins
Gross margin is 28.18%, with operating margin of -327.19%, and net profit margin of -339.20%.
- Gross Margin
- 28.18%
- Operating Margin
- -327.19%
- Pretax Margin
- -339.03%
- Net Profit Margin
- -339.20%
- EBITDA Margin
- -316.35%
- EBIT Margin
- -325.58%
